Enzalutamide Gains Approval in China for mCRPC

November 27, 2019 – China’s National Medical Products Administration has granted approval to enzalutamide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic following progression on androgen deprivation therapy (ADT) in whom chemotherapy is not yet clinically indicated. The approval is partly based on findings from the Asian, international, double-blind, placebo-controlled, phase … (leggi tutto)